American Hospital Association wants all healthcare workers vaccinated

The AHA is urging all provider organizations to require COVID-19 vaccinations for their healthcare workers while also pledging support to organizations that adopt such mandates.

In a policy statement issued late Wednesday, AHA emphasizes that the COVID vaccines now in circulation can protect not only healthcare workers themselves but also the patients and co-workers around whom they work.

Unvaccinated individuals face “a substantial risk of severe illness and death,” AHA notes, and the most vulnerable are those with underlying health conditions, “like many patients in hospitals or who are seen in hospital-based ambulatory settings.”

AHA acknowledges that hospitals and health systems will need to take into account local laws and related factors as they work out how—and whether—to adopt mandatory vaccination.

However, the group is not mincing words on overall where it stands.

“COVID-19 vaccines protect healthcare personnel when working both in healthcare facilities and in the community,” AHA states. “They provide strong protection against workers unintentionally carrying the disease to work and spreading it to patients and peers.”

In a succinct press release, AHA’s president and CEO, Rick Pollack, adds:

The evidence is clear: COVID-19 vaccines are safe and effective in reducing both the risk of becoming infected and spreading the virus to others. The AHA supports hospitals and health systems that choose, based on local factors, to mandate COVID-19 vaccines for their workforce. Doing so will help protect the health and well-being of health care personnel and the patients and communities they proudly serve.”

Press release here, full policy statement here.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.